Resveratrol inhibits the growth of gastric cancer via the Wnt/β-catenin pathway

Dai,Hui; Deng,Hou-Bo; Wang,Ya-Hong; Guo,Jia-Juan

doi:10.3892/ol.2018.8772

Resveratrol inhibits the growth of gastric cancer via the Wnt/β-catenin pathway

Authors:
- Hui Dai
- Hou-Bo Deng
- Ya-Hong Wang
- Jia-Juan Guo
View Affiliations

Affiliations: Department of Tumor and Blood Disease, Changchun University of Traditional Chinese Medicine Affiliated Hospital, Changchun, Jilin 130021, P.R. China, Department of Liver, Spleen and Stomach Disease, Changchun University of Traditional Chinese Medicine Affiliated Hospital, Changchun, Jilin 130021, P.R. China, Department of Cardiovascular Disease, Changchun University of Traditional Chinese Medicine Affiliated Hospital, Changchun, Jilin 130021, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8772
Pages: 1579-1583
Copyright: © Dai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inhibitory effect of resveratrol on the growth of gastric cancer cells through downregulation of the Wnt/β-catenin signaling pathway were studied. First we determined the effective concentration of resveratrol on the growth and proliferation of MGC-803 gastric cancer cells. Methylthiazolyl tetrazolium assay showed that resveratrol significantly inhibited the proliferation of MGC-803 cells in a dose-dependent manner. Resveratrol induced apoptotic morphological changes in MGC-803 cells. Reverse transcription-polymerase chain reaction and western blot analysis showed that resveratrol downregulated the expression of three important components of the Wnt signaling pathway, β-catenin, c-myc, and cyclin D1, at the mRNA and protein levels. Overall, resveratrol inhibits the growth of MGC-803 cells by inhibiting the Wnt signaling pathway. This study provides a new idea and direction for the antitumor mechanism of resveratrol.

View Figures

View References

1	Lv Y, Song L, Chang L, Liu Y, Zhang X, Wang Y, Wang L and Liu W: Bevacizumab followed by chemotherapy is potential therapy for gastric cancer. J BUON. 21:1466–1470. 2016.PubMed/NCBI
2	Shu B, Lei S, Li F, Hua S, Chen Y and Huo Z: Laparoscopic total gastrectomy compared with open resection for gastric carcinoma: A case-matched study with long-term follow-up. J BUON. 21:101–107. 2016.PubMed/NCBI
3	Shen YH, Xie ZB, Yue AM, Wei QD, Zhao HF, Yin HD, Mai W, Zhong XG and Huang SR: Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci. 20:1283–1287. 2016.PubMed/NCBI
4	Zhou SF, Yin JB, Yang H, Zhong J and An P: Application value of stomach filling ultrasonography and intravenous contrast agents in diagnosis of advanced gastric cancer. Eur Rev Med Pharmacol Sci. 20:3206–3210. 2016.PubMed/NCBI
5	Zhang N, Wang AY, Wang XK, Sun XM and Xue HZ: GAS5 is downregulated in gastric cancer cells by promoter hypermethylation and regulates adriamycin sensitivity. Eur Rev Med Pharmacol Sci. 20:3199–3205. 2016.PubMed/NCBI
6	Mello BS, Lucena AF, Echer IC and Luzia MF: Patients with gastric cancer submitted to gastrectomy: An integrative review. Rev Gaúcha Enferm. 31:803–811. 2010.(In Portuguese). View Article : Google Scholar
7	Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
8	Olaku O and White JD: Herbal therapy use by cancer patients: A literature review on case reports. Eur J Cancer. 47:508–514. 2011. View Article : Google Scholar : PubMed/NCBI
9	Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
10	Gescher A, Steward WP and Brown K: Resveratrol in the management of human cancer: How strong is the clinical evidence? Ann N Y Acad Sci. 1290:12–20. 2013. View Article : Google Scholar : PubMed/NCBI
11	Crew KD and Neugut AI: Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 31:450–464. 2004. View Article : Google Scholar : PubMed/NCBI
12	Miyoshi K and Hennighausen L: Beta-catenin: A transforming actor on many stages. Breast Cancer Res. 5:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
13	Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y and Hirohashi S: Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology. 59:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
14	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.PubMed/NCBI
15	Lim SC and Lee MS: Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer. Oncol Rep. 9:915–928. 2002.PubMed/NCBI
16	Roh MS, Hong SH, Jeong JS, Kwon HC, Kim MC, Cho SH, Yoon JH and Hwang TH: Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci. 19:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
17	Utsuki S, Sato Y, Oka H, Tsuchiya B, Suzuki S and Fujii K: Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 57:187–192. 2002. View Article : Google Scholar : PubMed/NCBI
18	Ehrlich D, Bruder E, Thome MA, Gutt CN, von Knebel Doeberitz M, Niggli F, Perantoni AO and Koesters R: Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol. 13:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M and Wang Y: Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J Ethnopharmacol. 149:601–612. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu YZ, Wu K, Huang J, Liu Y, Wang X, Meng ZJ, Yuan SX, Wang DX, Luo JY, Zuo GW, et al: The PTEN/PI3K/Akt and Wnt/β-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation. Int J Oncol. 45:104–112. 2014. View Article : Google Scholar : PubMed/NCBI